Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation

Table 2 Summary of patient, liver function, tumour and treatment characteristics

	Range (%)
Age	59 (31-66)
Gender (male), n (%)	6 (100)
Type of graft
Whole	4 (67)
Right lobe	2 (33)
Within UCSF, n (%)	4 (67)
Time to first recurrence (mo)	18.5 (1.2-69.4)
Time to index recurrence (mo)	66.5 (1.2-86.7)
ECOG	1 (0-1)
Bilirubin (umol/L)	9 (4-23)
Albumin (g/L)	43 (39-47)
ALT (U/L)	28 (19-44)
AST (U/L)	33 (18-58)
INR	1.0 (1.0-1.5)1
Platelet (× 109/L)	124 (43-255)
Creatinine (umol/L)	107 (78-121)
Index lesion as first recurrence, n (%)	4 (44)
Number of index lesions	1 (1-2)
Tumour size (cm)	2.3 (0.7-3.6)
IVC invasion, n (%)	2 (22)
Distant recurrence, n (%)	1 (11)
AFP (ng/mL)	4 (2-1354)
Prescribed dose (Gy)	45 (37.5-50)
Number of fractions	5 (5-6)
Dose per fraction (Gy)	8 (7.5-10)
Treatment duration (d)	5 (5-14)
Concomitant sysetmic treatment, n (%)	6 (100)

¹One patient on warfarin had INR ≥ 1.5. ECOG: Eastern Cooperative Oncology Group; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; USCF: University of California San Francisco; IVC: Inferior vena cava.